vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Intellicheck, Inc. (IDN). Click either name above to swap in a different company.
Arbutus Biopharma Corp is the larger business by last-quarter revenue ($10.7M vs $6.6M, roughly 1.6× Intellicheck, Inc.). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs 23.4%, a 0.1% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 11.8%). Over the past eight quarters, Intellicheck, Inc.'s revenue compounded faster (19.1% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Intellicheck, Inc. is a US-based technology company specializing in identity verification and fraud prevention solutions. It develops AI-powered tools to validate government-issued identification documents, streamline customer onboarding, and mitigate identity theft risks for clients across finance, retail, healthcare and public sector segments.
ABUS vs IDN — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $6.6M |
| Net Profit | $2.5M | $1.6M |
| Gross Margin | — | 91.4% |
| Operating Margin | 13.9% | 22.5% |
| Net Margin | 23.5% | 23.4% |
| Revenue YoY | 522.2% | 11.8% |
| Net Profit YoY | 112.7% | 218.0% |
| EPS (diluted) | $0.01 | $0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $6.6M | ||
| Q3 25 | — | $6.0M | ||
| Q2 25 | $10.7M | $5.1M | ||
| Q1 25 | — | $4.9M | ||
| Q4 24 | — | $5.9M | ||
| Q3 24 | — | $4.7M | ||
| Q2 24 | — | $4.7M | ||
| Q1 24 | — | $4.7M |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $290.0K | ||
| Q2 25 | $2.5M | $-251.0K | ||
| Q1 25 | — | $-318.0K | ||
| Q4 24 | — | $488.0K | ||
| Q3 24 | — | $-837.0K | ||
| Q2 24 | — | $-127.0K | ||
| Q1 24 | — | $-442.0K |
| Q4 25 | — | 91.4% | ||
| Q3 25 | — | 90.5% | ||
| Q2 25 | — | 89.8% | ||
| Q1 25 | — | 89.7% | ||
| Q4 24 | — | 91.1% | ||
| Q3 24 | — | 91.0% | ||
| Q2 24 | — | 90.5% | ||
| Q1 24 | — | 90.7% |
| Q4 25 | — | 22.5% | ||
| Q3 25 | — | 4.0% | ||
| Q2 25 | 13.9% | -5.8% | ||
| Q1 25 | — | -7.1% | ||
| Q4 24 | — | 8.1% | ||
| Q3 24 | — | -19.3% | ||
| Q2 24 | — | -4.6% | ||
| Q1 24 | — | -11.2% |
| Q4 25 | — | 23.4% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | 23.5% | -4.9% | ||
| Q1 25 | — | -6.5% | ||
| Q4 24 | — | 8.2% | ||
| Q3 24 | — | -17.8% | ||
| Q2 24 | — | -2.7% | ||
| Q1 24 | — | -9.4% |
| Q4 25 | — | $0.08 | ||
| Q3 25 | — | $0.01 | ||
| Q2 25 | $0.01 | $-0.01 | ||
| Q1 25 | — | $-0.02 | ||
| Q4 24 | — | $0.02 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | — | $-0.01 | ||
| Q1 24 | — | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $9.7M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $20.7M |
| Total Assets | $103.3M | $24.5M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $9.7M | ||
| Q3 25 | — | $7.2M | ||
| Q2 25 | $37.4M | $8.6M | ||
| Q1 25 | — | $5.1M | ||
| Q4 24 | — | $4.7M | ||
| Q3 24 | — | $5.7M | ||
| Q2 24 | — | $7.3M | ||
| Q1 24 | — | $9.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $20.7M | ||
| Q3 25 | — | $18.9M | ||
| Q2 25 | $83.0M | $18.0M | ||
| Q1 25 | — | $17.6M | ||
| Q4 24 | — | $17.7M | ||
| Q3 24 | — | $16.7M | ||
| Q2 24 | — | $17.3M | ||
| Q1 24 | — | $17.2M |
| Q4 25 | — | $24.5M | ||
| Q3 25 | — | $25.3M | ||
| Q2 25 | $103.3M | $23.1M | ||
| Q1 25 | — | $24.6M | ||
| Q4 24 | — | $20.9M | ||
| Q3 24 | — | $20.7M | ||
| Q2 24 | — | $21.9M | ||
| Q1 24 | — | $22.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $2.4M |
| Free Cash FlowOCF − Capex | — | $2.4M |
| FCF MarginFCF / Revenue | — | 36.0% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | -6.24× | 1.54× |
| TTM Free Cash FlowTrailing 4 quarters | — | $4.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.4M | ||
| Q3 25 | — | $-1.7M | ||
| Q2 25 | $-15.7M | $3.1M | ||
| Q1 25 | — | $750.0K | ||
| Q4 24 | — | $-1.3M | ||
| Q3 24 | — | $-1.1M | ||
| Q2 24 | — | $-1.2M | ||
| Q1 24 | — | $869.0K |
| Q4 25 | — | $2.4M | ||
| Q3 25 | — | $-1.8M | ||
| Q2 25 | — | $3.1M | ||
| Q1 25 | — | $741.0K | ||
| Q4 24 | — | $-1.3M | ||
| Q3 24 | — | $-1.1M | ||
| Q2 24 | — | $-1.2M | ||
| Q1 24 | — | $860.0K |
| Q4 25 | — | 36.0% | ||
| Q3 25 | — | -29.2% | ||
| Q2 25 | — | 60.9% | ||
| Q1 25 | — | 15.1% | ||
| Q4 24 | — | -22.4% | ||
| Q3 24 | — | -23.1% | ||
| Q2 24 | — | -25.5% | ||
| Q1 24 | — | 18.4% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | 0.0% | 0.3% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | — | 1.54× | ||
| Q3 25 | — | -5.99× | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -2.71× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
